Drugs Made In America Acquisition Corp. (DMAAU) Enterprise Value (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Enterprise Value came in at -$6137.0 in Q4 2025, down 354.26% YoY from $2413.7 in Q4 2024, and down 755.93% on a QoQ basis from -$717.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Enterprise Value (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Enterprise Value data on file, last reported at -$6137.0 in Q4 2025.
- Quarterly Enterprise Value fell 354.26% year-over-year to -$6137.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6137.0 (down 354.26% YoY) and the FY2025 annual result came in at -$6137.0, down 354.26% from the prior year.
- Enterprise Value declined to -$6137.0 in Q4 2025, from -$717.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$717.0 in Q3 2025 to a low of -$6137.0 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,137.00 |
| Sep 30, 2025 | -717.00 |
| Jun 30, 2025 | -822.00 |
| Mar 31, 2025 | -923.00 |
| Dec 31, 2024 | -1,351.00 |